Noisy wake-up call for HIV {#cesec10}
==========================

The ability of HIV to enter a [latent state](http://dx.doi.org/10.1126/science.1250220){#interrefs10} is a major barrier to finding a cure for HIV/AIDS. Researchers now report that compounds that induce the stochastic fluctuations ("noise") in gene expression around the mean expression level that often drives cell-fate decisions could help to reactivate latent HIV. In a screen of bioactive small molecules, the researchers identified more than 80 compounds that modulated HIV gene-expression noise without changing mean expression. Notably, these noise-modulating compounds synergised with known transcriptional activators to reactivate HIV in latently infected human cells.

Coronavirus antivirals {#cesec20}
======================

The recent emergence of two highly pathogenic human coronaviruses has highlighted the need to [develop drugs](http://dx.doi.org/10.1371/journal.ppat.1004166){#interrefs20} to combat coronavirus infections. A promising lead is a compound called K22, which was identified in a screen for molecules with activity against a circulating human coronavirus that causes common cold-like symptoms. K22---which impairs the formation of the host-derived double membrane vesicles that coronaviruses need for viral RNA synthesis---inhibits a broad range of coronaviruses, including Middle East respiratory syndrome coronavirus. The recruitment of cellular membranes may therefore represent a target for anticoronavirus drug development.

H10 influenza virus threat {#cesec30}
==========================

Since December, 2013, three cases of infection with the H10N8 avian influenza virus have been recorded and two patients have died. But does H10N8 pose an epidemic threat? To answer this question, researchers have examined the [receptor-binding](http://dx.doi.org/10.1038/nature13443){#interrefs30} properties of the haemagglutinin of a previously isolated avian H10 virus. Although this virus has a high avidity for human receptors (approaching that of the 1918 H1N1 pandemic virus), its avidity for avian receptors is much higher. These results explain the ability of H10N8 to infect people but suggest that the presence of receptors for avian haemagglutinin in human airway mucins should prevent widespread human infection.

RNAse YbeY and cholera {#cesec40}
======================

The highly conserved bacterial endoribonuclease [YbeY](http://dx.doi.org/10.1371/journal.ppat.1004175){#interrefs40} is involved in rRNA processing and in ribosome quality control under stress in *Escherichia coli*. YbeY is not essential in *E coli* but a new study indicates that it is crucial for these processes in *Vibrio cholerae*. The study also shows that production of cholera toxin and virulence-associated RNAs is reduced and colonisation of mice and biofilm formation are lost in a *V cholerae* strain partly depleted for YbeY, and that YbeY is part of a core set of RNAses that is essential in many other pathogens. Together, these results identify YbeY as an attractive new antimicrobial target.

Dealing with skin infections {#cesec50}
============================

Acute skin infections caused by meticillin-resistant *Staphylococcus aureus* (MRSA) are a common reason for hospitalisation. Currently, their treatment involves daily antibiotic injections for 10 days or more but two reports suggest that lipoglycopeptide antibiotics could provide an alternative therapeutic approach. The first report describes the pooled analysis of two double-blind, randomised, non-inferiority trials in which patients with acute bacterial infections of the skin and skin structures received dalbavancin intravenously on [days 1 and 8](http://dx.doi.org/10.1056/NEJMoa1310480){#interrefs50}, or vancomycin intravenously for at least 3 days before switching to oral linezolid to complete their treatment. 80% of patients in both groups had an early clinical response (cessation of the spread of infection-related erythema and absence of fever at 48--72 h). The second report describes a similar trial in which patients received a [single](http://dx.doi.org/10.1056/NEJMoa1310422){#interrefs60} intravenous dose of oritavancin, or intravenous vancomycin twice daily for 7--10 days. Again, about 80% of patients in both groups showed an early clinical response. Dalbavancin received US Food and Drug Administration (FDA) approval for the treatment of skin infections on May 23, 2014, and a new drug application for oritavancin with priority review was filed with the FDA on Feb 19, 2014.
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Malaria control by bacteria {#cesec60}
===========================

The apparent absence of [natural wolbachia](http://dx.doi.org/10.1038/ncomms4985){#interrefs70} infections in anopheline mosquitoes has tempered hopes that it might be possible to use these maternally transmitted intracellular bacteria, which limit plasmodium parasite development in mosquitoes, to control malaria. Now, researchers have identified a new wolbachia strain in *Anopheles gambiae* mosquitoes in three villages in Burkina Faso. Wolbachia sequences were present across two seasons in both the male and female germline and were vertically transmitted from mother to offspring. These results support further investigation of the use of wolbachia infections for malaria control.
